Purpose of Review: Neuroscientific models of addiction have evolved over the past four decades from single-circuit dopamine frameworks to dual-process, tripartite, and multidimensional accounts. Despite these advances, existing models incompletely account for the lived experience of addiction and for developmental, social, and mental-health factors that contribute to heterogeneity in risk and...
Opioid use disorder (OUD) remains a major public health crisis in the United States, with mental health disorders substantially increasing risk severity. Emerging evidence suggests psychedelics may relate to reduced OUD risk. This exploratory study examined associations between lifetime psychedelic use and OUD severity and tested whether these associations varied by mental health impairment....
Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health–Dependent Associations in a National Survey
Several pilot studies have provided evidence supporting the potential of classic psychedelics like psilocybin in the treatment of substance use disorders (SUDs). If larger trials confirm efficacy, classic psychedelic-assisted psychotherapy may eventually be integrated into existing addiction treatments such as cognitive behavioral therapy, contingency management, and medication-assisted...